CAJ | 학술논문

目的探讨2型糖尿病(T2DM)患者尿Nephrin排泄的变化以及吡格列酮干预对其的影响.方法将98例T2DM患者随机分为磺脲类药物干预组(DS组)、吡格列酮干预组(DP组),观察治疗前后相关代谢指标及尿Nephrin排泄的变化,选择同期健康体检人群49名为正常对照(NC)组.结果 DP组、DS组患者FPG、HbA1c、尿白蛋白(UA1b)/尿肌酐(UCr)比值较NC组明显升高(P＜0.01).NC组尿中未检测到Nephrin;DP组干预后尿Nephrin/UCr比值明显下降(P＜0.01),DS组干预前后尿Nephrin/UCr比值的差异无统计学意义(P＞0.05).结论吡格列酮可降低T2DM患者尿Nephrin排泄,对肾小球足细胞有保护作用.
목적 탐토2형당뇨병(T2DM)환자뇨Nephrin배설적변화이급필격렬동간예대기적영향.방법 장98례T2DM환자수궤분위광뇨류약물간예조(DS조)、필격렬동간예조(DP조),관찰치료전후상관대사지표급뇨Nephrin배설적변화,선택동기건강체검인군49명위정상대조(NC)조.결과 DP조、DS조환자FPG、HbA1c、뇨백단백(UA1b)/뇨기항(UCr)비치교NC조명현승고(P＜0.01).NC조뇨중미검측도Nephrin;DP조간예후뇨Nephrin/UCr비치명현하강(P＜0.01),DS조간예전후뇨Nephrin/UCr비치적차이무통계학의의(P＞0.05).결론 필격렬동가강저T2DM환자뇨Nephrin배설,대신소구족세포유보호작용.
Objective To investigate the change of urinary Nephrin excretion and the effect of pioglitane on the change in the patients with T2DM． Method We examined various clinical indexes in normal control group, sulfonylurea group and pioglitazone group. Results The levels of FPG, HbA1c, and the ratio of UAlb to UCr were higher in type 2 diabetic patients than in normal control at basal line (P<0.05). There was no urinary Nephrin detected in normal control group, but Nephrin was found in the urine of diabetics. The ratio of urinary Nephrin to UCr was positively related with the ratio of UAlb to UCr. They all decreased after 12 weeks of therapy. The differences in the two ratios showed no statistical significance between pre-and post-therapy of sulfonylurea, but showed obvious statistical significance in pioglitazone group. Conclusion Pioglitazone could reduce the increased urinary Nephrin excretion and provide some podocyte protection in T2DM．